论文部分内容阅读
Current anticancer drugs used in the clinic suffer trom problems such as poor water solubility,rapid clearance,and nonspecific distribution in the normal tissue.Recent advances in dendrimer nanotechnology have shown that it is possible to develop a carrier system that can specifically target cancer cells via a receptor-mediated active targeting strategy [1].